n terminal pro bnp  (Elabscience Biotechnology)

Journal: Molecular Medicine Reports

Article Title: Prenatal lipopolysaccharide exposure programs cardiac fibrosis via dysregulating of connexin 43 in offspring rats

doi: 10.3892/mmr.2026.13830

Figure Lengend Snippet: BW of offspring rats from 1-day to 16-week-old (A). Heart damages in offspring at the age of 8 and 16 weeks, including the ratios (B) LVW/BW, (C) HW/BW and (D) NT-proBNP level in serum. Concentration of Ang II in (E) left ventricle and (F) serum. Data are presented as mean ± SD. n=10 in each group (A-C) and n=7 in each group (D-F). *P<0.05, **P<0.01 vs Con. BW, body weight; HW, heart weight; LVW, left ventricular weight; NT-proBNP, N-terminal pro-brain natriuretic peptide; Ang II, angiotensin II; Con, control; LPS, lipopolysaccharide.

Article Snippet: Serum concentrations of N-terminal pro-BNP (NT-proBNP; cat. no. E-EL-R3023) and Ang II, along with myocardial tissue levels of Ang II (cat. no. E-EL-R1430c), were quantified using commercial ELISA kits (Elabscience Biotechnology Co., Ltd.) following manufacturer protocols.

Techniques: Concentration Assay, Control

Journal: JACC: Basic to Translational Science

Article Title: Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients

doi: 10.1016/j.jacbts.2026.101510

Figure Lengend Snippet: Higher Elevated Troponin-I (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide (BNP) levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .

Article Snippet: High-sensitivity cardiac troponin I (hs-cTnI) and BNP levels were measured using chemiluminescent microparticle immunoassays on the Abbott Architect platform (Abbott Laboratories). hs-cTnI was quantified using the Architect STAT High Sensitive Troponin-I assay, while BNP was measured using the Architect BNP assay.

Techniques: